488 results on '"Maurel, Joan"'
Search Results
2. A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
3. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
4. Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
5. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
6. Prognostic value of cutaneous reinnervation with GAP-43 in oxaliplatin-induced neuropathy
7. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor
8. Retifanlimab and the Arginase Inhibitor CB-1158 Show Low Activity in Microsatellite-Stable Colorectal Cancer Patient-Derived Organoids Co-Cultured with Tumor-Infiltrating Lymphocytes
9. Retifanlimab and the arginase inhibitor CB-1158 show low activity in microsatellite-stable colorectal cancer patient-derived organoids co-cultured with tumor-infiltrating lymphocytes
10. The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas
11. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial
12. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
13. Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma
14. Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study
15. Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402
16. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
17. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
18. Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma
19. Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
20. Data from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
21. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
22. Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis
23. A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
24. Cancer informative biomarker signature
25. Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
26. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study
27. Supplementary Data from A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer
28. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients
29. Additional file 1 of A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
30. Cytology Smears: An Enhanced Alternative Method for Colorectal Cancer pN Stage—A Multicentre Study
31. A metastasis‐associated microRNA‐based liquid biopsy signature for risk‐stratification in colorectal cancer: a multicenter cohort study
32. Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer
33. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
34. A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes
35. Prognostic value of cutaneous reinnervation with GAP-43 in oxaliplatin-induced neuropathy
36. A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting.
37. PBRM1 genomic alterations as a predictive biomarker to immune checkpoint inhibitors (ICI) and/or anti-angiogenic therapies (anti-VEGF) in metastatic renal cell carcinoma (mRCC): A systematic review and meta-analysis.
38. An Immune-metabolic signature (IMMETCOLS) identifies three clusters in mCRC with different immune-phenotype distribution and potential clinical implications.
39. Upregulation of Trefoil Factor 3 (TFF3) After Rectal Cancer Chemoradiotherapy Is an Adverse Prognostic Factor and a Potential Therapeutic Target
40. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)
41. Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
42. Impact of microscopic incomplete resection for colorectal liver metastases on surgical margin recurrence: R1‐Contact vs. R1<1mm margin width.
43. EUS and magnetic resonance imaging in the staging of rectal cancer: a prospective and comparative study
44. LoVo Colon Cancer Cells Resistant to Oxaliplatin Overexpress c-MET and VEGFR-1 and Respond to VEGF With Dephosphorylation of c-MET
45. Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials
46. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor
47. A novel gene signature unveils three distinct immunemetabolic rewiring patterns conserved across diverse tumor types and associated with outcomes.
48. Evaluación económica de XELOX y FOLFOX-4 en el tratamiento en primera línea de cáncer colorrectal metastásico en España
49. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer
50. Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.